Trial · NCT02119676
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Substudy 1: Ruxolitinib + Regorafenib | 4.6 | 95% Confidence Interval 3.5 to 5.4 | months | |
| Overall Survival (OS) | Substudy 1: Placebo + Regorafenib | 5.3 | 95% Confidence Interval 4.3 to 6.0 | months | |
| Overall Survival (OS) | Substudy 2: Ruxolitinib + Regorafenib | 11.4 | 95% Confidence Interval 9.0 to 13.2 | months | |
| Overall Survival (OS) | Substudy 2: Placebo + Regorafenib | 10.9 | 95% Confidence Interval 7.2 to NA | months | |
| Progression Free Survival (PFS) | Substudy 1: Ruxolitinib + Regorafenib | 2.2 | 95% Confidence Interval 1.9 to 3.0 | months | |
| Progression Free Survival (PFS) | Substudy 1: Placebo + Regorafenib | 2.1 | 95% Confidence Interval 1.8 to 2.7 | months | |
| Progression Free Survival (PFS) | Substudy 2: Ruxolitinib + Regorafenib | 3.5 | 95% Confidence Interval 3.0 to 3.8 | months | |
| Progression Free Survival (PFS) | Substudy 2: Placebo + Regorafenib | 2.0 | 95% Confidence Interval 1.9 to 3.1 | months | |
| Overall Response Rate (ORR) | Substudy 1: Ruxolitinib + Regorafenib | 0.0 | 95% Confidence Interval 0.0 to 4.2 | percentage of responders | |
| Overall Response Rate (ORR) | Substudy 1: Placebo + Regorafenib | 0.0 | 95% Confidence Interval 0.0 to 4.1 | percentage of responders | |
| Overall Response Rate (ORR) | Substudy 2: Ruxolitinib + Regorafenib | 2.7 | 95% Confidence Interval 0.6 to 7.8 | percentage of responders | |
| Overall Response Rate (ORR) | Substudy 2: Placebo + Regorafenib | 4.5 | 95% Confidence Interval 1.5 to 10.2 | percentage of responders | |
| Percentage of Participants Achieving Disease Control | Substudy 1: Ruxolitinib + Regorafenib | 40.2 | 95% Confidence Interval 29.9 to 51.3 | percentage of participants | |
| Percentage of Participants Achieving Disease Control | Substudy 1: Placebo + Regorafenib | 34.1 | 95% Confidence Interval 24.3 to 45.0 | percentage of participants | |
| Percentage of Participants Achieving Disease Control | Substudy 2: Ruxolitinib + Regorafenib | 61.8 | 95% Confidence Interval 52.1 to 70.9 | percentage of participants | |
| Percentage of Participants Achieving Disease Control | Substudy 2: Placebo + Regorafenib | 36.9 | 95% Confidence Interval 28.0 to 46.6 | percentage of participants | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Substudy 1: Ruxolitinib + Regorafenib | Participants with any TEAEs | 100.0 | percentage of participants | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Substudy 1: Placebo + Regorafenib | Participants with any TEAEs | 100.0 | percentage of participants | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Substudy 2: Ruxolitinib + Regorafenib | Participants with any TEAEs | 100.0 | percentage of participants | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Substudy 2: Placebo + Regorafenib | Participants with any TEAEs | 99.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02119676/results